Clinic
Mission Hospital, INC.
Mission Hospital, INC. was paid $7.84M by Medicaid between Mar 2019 and Dec 2024, across 100 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoMISSION HOSPITAL, INC.
MISSION, TX 78572
MISSION, TX 78572
33aNPI1205833985assigned 07/07/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$7.84M
24GClaims196,969
24DCodes billed100
24AFirst – last monthMar 2019 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#58 of 320
Median peer was paid$205K
This provider vs. median38×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 1,749 | $27K | |
| 2020 | 5,650 | $300K | |
| 2021 | 42,204 | $1.52M | |
| 2022 | 62,862 | $2.44M | |
| 2023 | 60,009 | $2.53M | |
| 2024incomplete | 24,495 | $1.01M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 12,146 | 11,310 | $2.67M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 23% | 7,490 | 6,245 | $1.79M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.7% | 15,118 | 14,485 | $681K |
| G0378 | Hospital observation service, per hour | 5.1% | 1,731 | 1,362 | $400K |
| 87428 | 2.6% | 3,787 | 3,727 | $206K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.0% | 2,169 | 2,120 | $155K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 3,994 | 3,353 | $137K |
| 71045 | Radiologic examination, chest; single view | 1.7% | 5,652 | 5,282 | $136K |
| 80053 | Comprehensive metabolic panel | 1.6% | 12,608 | 11,468 | $126K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 18,630 | 15,892 | $125K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.5% | 2,480 | 2,386 | $121K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 5,616 | 5,253 | $101K |
88 more codes
| 59025 | Fetal non-stress test | 1.3% | 1,097 | $100K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.3% | 196 | $99K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 1,614 | $95K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,875 | $72K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 475 | $51K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,867 | $51K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 934 | $49K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 494 | $43K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 684 | $43K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 255 | $42K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,457 | $38K |
| 76801 | <1% | 335 | $36K | |
| 76818 | <1% | 287 | $31K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 642 | $30K |
| 83690 | <1% | 4,513 | $29K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,861 | $28K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 606 | $26K |
| 87070 | <1% | 2,589 | $25K | |
| 84703 | <1% | 2,800 | $22K | |
| 82150 | <1% | 3,644 | $22K | |
| 83880 | <1% | 1,454 | $20K | |
| 81003 | <1% | 9,097 | $19K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 159 | $14K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 215 | $13K |
| 84484 | <1% | 2,625 | $13K | |
| 84702 | <1% | 934 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 555 | $10K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,500 | $10K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,128 | $9K |
| 87486 | <1% | 197 | $8K | |
| 87581 | <1% | 194 | $8K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 620 | $8K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 232 | $8K |
| 85730 | <1% | 3,123 | $8K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 214 | $7K |
| 87040 | <1% | 1,061 | $6K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 94 | $6K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 29 | $6K |
| 87088 | <1% | 997 | $6K | |
| 85610 | <1% | 3,119 | $6K | |
| 80061 | Lipid panel | <1% | 356 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,675 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,463 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,501 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 161 | $4K |
| 82607 | <1% | 203 | $3K | |
| 82948 | <1% | 2,039 | $3K | |
| 82746 | <1% | 189 | $3K | |
| 96376 | <1% | 216 | $3K | |
| 83525 | <1% | 178 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 235 | $2K |
| 83605 | <1% | 471 | $2K | |
| 84439 | <1% | 153 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 75 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 69 | $1K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,125 | $1K |
| 87186 | <1% | 354 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 24 | $1K |
| 87077 | <1% | 347 | $1K | |
| 86901 | <1% | 547 | $1K | |
| 80076 | <1% | 98 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 50 | $807.11 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 12 | $642.91 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 798 | $641.42 |
| 87400 | <1% | 50 | $591.30 | |
| 86900 | <1% | 240 | $529.13 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 34 | $524.99 |
| 82947 | <1% | 116 | $498.07 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,327 | $426.99 |
| 83735 | <1% | 82 | $232.70 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 13 | $157.84 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 15 | $145.63 |
| S0028 | Injection, famotidine, 20 mg | <1% | 296 | $122.71 |
| 87340 | <1% | 27 | $115.96 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 55 | $105.69 |
| 85651 | <1% | 17 | $85.94 | |
| 87071 | <1% | 51 | $78.28 | |
| 72100 | <1% | 13 | $75.58 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 171 | $32.51 |
| 86140 | <1% | 26 | $30.01 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 219 | $20.90 |
| 83520 | <1% | 169 | $15.71 | |
| 87205 | <1% | 19 | $7.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 286 | $4.32 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 47 | $0.12 |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | 0% | 48 | $0.00 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 72 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 44 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSURROCK, LESTER (CFO)
| Provider | Location | Paid |
|---|---|---|
| Knapp Medical Center | Weslaco, TX | $6.62M |
| Mission Hospital INC | Mission, TX | $106K |
| Mission Doctors Group | Mission, TX | $69K |
| Knapp Medical Group | Weslaco, TX | $59K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.